Category Archives: Gene Therapy Clinics

Global Genetic Testing Services Market is Expected to Reach USD 67.1 Billion by 2025 : Fior Markets – GlobeNewswire

By adminFebruary 27, 2020Gene Therapy Clinics

Newark, NJ, Feb. 25, 2020 (GLOBE NEWSWIRE) -- As per the report published by Fior Markets, theglobal genetic testing services market is expected to grow from USD 34.5 Billion in 2017 to USD 67.1 Billion by 2025 at a CAGR of 8.72% during the forecast period 2018-2025. Rising prevalence of genetic diseases, awareness among population, growing adoption of genetic testing services, and demand of genetic testing in developed countries, growing demand for personalized medicine, growing government initiatives and increased R&D activities in the genetic testing market are the factors that is driving genetic testing services market.

Genetic testing is used in the analysis of the changes in chromosomes, proteins, or genes caused by any suspected genetic condition or disease. It is also used in the diagnosis of cancer and plan the treatment. Several genetic tests are used such as new-born screening, prenatal testing, pre-implantation testing, carrier testing, etc. Numerous methods such as chromosomal method, molecular method and biochemical method are used for genetic testing. It is performed for the identification of risk factors, to screen the new-borns, and also in forensics. According to the report by WHO, sickle cell anaemia is one of the most common genetic disorders among people whose ancestors come from Sub-Saharan Africa, South America, Cuba, Central America, Saudi Arabia, India, and Mediterranean countries. Genetic tests in combination with other genomic technologies predict risk of an individual to a disease and also increase the opportunities for players in pharmaceutical industry to grow. For instance, and provides genetic makeup tests to the consumers. Company also recommends genetic counsellors based on results to help the consumers about the better testing of genes, and the inherited diseases.

Advancements in genetic testing technologies, rising cases of genetic diseases and growing awareness are driving the testing market. In addition, emerging markets hold great potential for growth of due to growing awareness and increase in patients in these regions. High cost and lack of experienced professionals are some of the factors restraining the growth of the market. However, Shift from clinical science to bioinformatics is also leading to high rate of adoption of genetic testing technology, which in turn is augmenting the growth of the market in coming years.

DOWNLOAD FREE SAMPLE REPORT AThttps://www.fiormarkets.com/report-detail/362223/request-sample

Key players operating in the global genetic testing services market include Laboratory Corporation of America Holdings, Genomic Health, Inc., NeoGenomics Laboratories, Inc., Quest Diagnostics, Eurofins Scientific, Ambry Genetics, Hoffmann-La Roche Ltd, Illumina, Inc., CENTOGENE AG, 23andMe, Sequenom, GeneDx, Abbott, Cepheid Inc., ELITech Group, Verinata Health, Inc and others. Top players of the market are making efforts in R&D to increase their footprint in the market.

The predictive & presymptomatic testing is dominating the segment and was valued around USD 12.17 billion in 2017

The test type segment includes prenatal testing, newborn screening, predictive and presymptomatic testing, pharmacogenomic testing. The predictive & presymptomatic testing is dominating the segment and was valued around USD 12.17 billion in 2017. Detection of diseases at early stage minimizes the severity of diseases leading to reduced mortality rate. Increasing prevalence of chronic diseases around the world is expected to augment the segment growth over the forecast period.

The oncology segment dominated the application segment and is expected to register the highest CAGR of 10.07% in the forecast period

The application segment is divided into segments such as oncology, infectious diseases and autoimmune diseases. The oncology segment dominated the application segment and is expected to register the highest CAGR of 10.07% in the forecast period. Timely diagnosis save lives and reduce the number of deaths. According to, The Institute for Health Metrics and Evaluation (IHME), around 8.9 million cancer deaths were recorded in 2016 caused by inheriting genetic mutation. Rising prevalence of various types of cancer such as prostate cancer, breast cancer and lung cancer coupled with increasing awareness pertaining to early detection of cancer are expected to stimulate the growth of the market.

The hospital-based laboratories segment is dominating the genetic testing services market and held the largest market share of 38.21% in 2017

The service provider segment is classified into hospital-based laboratories, diagnostic laboratories and specialty clinics. The hospital-based laboratories segment is dominating the genetic testing services market and held the largest market share of 38.21% in 2017. Advanced infrastructure and increasing number of hospitals in developing economies are driving the growth of the market.

Browse full report with TOC athttps://www.fiormarkets.com/report/global-genetic-testing-services-market-by-test-type-362223.html

Regional Segment Analysis of the Genetic Testing Services Market

The regions analysed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. North America region dominated the global genetic testing services market with the largest share and was valued around USD 15.180 Billion in 2017 where as Asia Pacific region is the fastest growing region in the market. North America region is dominating the market due to developed infrastructure, increase in health care investments and presence of large number of academic and research institutes are key factors leading to the growth of the market. Asia Pacific is anticipated to register highest growth in the forecast period. Increase in the prevalence of infectious disease, increasing awareness about the advantages of predictive testing, and rise in the adoption of advanced technology for clinical applications are some of the major factors offering growth opportunities to the genetic testing services market.

About the report:

The global genetic testing services market is analysed on the basis of value (USD Billion). All the segments have been analyzed on global, regional and country basis. The study includes the analysis of more than 30 countries for each segment. The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The study includes porters five forces model, attractiveness analysis, raw material analysis, supply, demand analysis, competitor position grid analysis, distribution and marketing channels analysis.

For Instant Purchase:

Customization of the Report:

The report can be customized as per client requirements. For further queries, you can contact us onsales@fiormarkets.comor +1-201-465-4211. Our executives will be pleased to understand your requirements and offer you the best-suited reports.

About Fior Markets

Fior Markets is a futuristic market intelligence company, helping customers flourish their business strategies and make better decisions using actionable intelligence. With transparent information pool, we meet clients objectives, commitments on high standard and targeting possible prospects for SWOT analysis and market research reports. Fior Markets deploys a wide range of regional and global market intelligence research reports including industries like technology, pharmaceutical, consumer goods, food and beverages, chemicals, media, materials and many others. Our Strategic Intelligence capabilities are purposely planned to boost your business extension and elucidate the vigor of diverse industry. We hold distinguished units of highly expert analysts and consultants according to their respective domains. The global market research reports we provide involve both qualitative and quantitative analysis of current market scenario as per the geographical regions segregated and comprehensive performance in different regions with global approach. In addition, our syndicated research reports offer a packaged guide to keep companies abreast of the upcoming major restyle in their domains. Fior Markets facilitates clients with research analysis that are customized to their exact requirements, specifications and challenges, whether it is comprehensive desk research, survey work, composition of multiple methods, in-detailed interviewing or competitive intelligence. Our research experts are experienced in matching the exact personnel and methodology to your business need.

Avinash DHead of Business DevelopmentPhone:+1-201-465-4211Email:sales@fiormarkets.comWeb:www.fiormarkets.com

To know more market research reports and industry analysis, visit our associate website: https://www.magnifierresearch.com

Go here to see the original:
Global Genetic Testing Services Market is Expected to Reach USD 67.1 Billion by 2025 : Fior Markets - GlobeNewswire

Global Genetic Testing Services Market is Expected to Reach USD 67.1 Billion by 2025 : Fior Markets – Yahoo Finance

By adminFebruary 26, 2020Gene Therapy Clinics

Global Genetic Testing Services Market by Test Type (Prenatal Testing, Newborn Screening, Predictive and Presymptomatic Testing), Application, Service Provider, Region, Global Industry Analysis, Market Size, Share, Growth, Trends, and Forecast 2018 to 2025

DOWNLOAD FREE SAMPLE REPORT AThttps://www.fiormarkets.com/report-detail/362223/request-sample

The predictive & presymptomatic testing is dominating the segment and was valued around USD 12.17 billion in 2017

The oncology segment dominated the application segment and is expected to register the highest CAGR of 10.07% in the forecast period

Story continues

The hospital-based laboratories segment is dominating the genetic testing services market and held the largest market share of 38.21% in 2017

Browse full report with TOC athttps://www.fiormarkets.com/report/global-genetic-testing-services-market-by-test-type-362223.html

Regional Segment Analysis of the Genetic Testing Services Market

About the report:

For Instant Purchase:

Customization of the Report:

About Fior Markets

Avinash DHead of Business DevelopmentPhone:+1-201-465-4211Email:sales@fiormarkets.comWeb:www.fiormarkets.com

To know more market research reports and industry analysis, visit our associate website: https://www.magnifierresearch.com

When Treating Women With Ovarian Cancer, Gynecologic Oncologist Emphasizes Openness And Dedication Throughout Journey – Forbes

By adminFebruary 24, 2020Gene Therapy Clinics

By Jodi Helmer

When Heidi E. Godoy, D.O., gynecologic oncologist, sees new ovarian cancer patients for the first time, she starts preparing them for the likelihood their cancer will return.

Dr. Heidi E. Godoy, gynecologic oncologist

For those unfamiliar with the disease, Godoys early focus on recurrence may seem premature. But she believes that being upfront about the realities of ovarian cancer is as important as discussing the initial treatment, which is typically surgery followed by platinum-based chemotherapy.

Ovarian cancer is difficult to diagnose, increasing the odds that it wont be discovered until it reaches an advanced stage. And in 85% of late-stage ovarian cancer cases, the disease recurs, according to research published in the International Journal of Surgical Oncology.1

One of the first conversations I have with patients outlines the relapse that often happens with ovarian cancer, said Godoy, who works in private practice in New York State and is affiliated with several hospitals there. I dont want it to be a surprise if the cancer returns.

Godoy also makes it a point to reassure women living with ovarian cancer that she will be with them throughout their cancer journey. Gynecologic oncologists, she explained, generally provide complete care, from diagnosis to surgery, for cancers affecting the ovaries, uterus, cervix, vulva and vagina. Holistic care is one of the reasons she pursued the subspecialty.

When I was going through medical school, I wanted a subspecialty that provided a lot of continuity of care, Godoy recalled. In gynecologic oncology, you develop such personalized, deep relationships with your patients.

Expert, Empathetic Care

For women living with ovarian cancer, receiving treatment from a gynecologic oncologist can simplify care and provide a sense of familiarity with their treatment teams. Research published in Frontiers In Oncology2 in 2015 shows that the highly-trained medical professionals also provide positive clinical outcomes.

Gynecologic oncologists perform complex procedures such as surgical debulkinga tumor-removal procedure that often affects other organsto remove the entire tumor and improve the prognosis. They are among the only specialists that perform surgical debulking, Godoy said. While surgery and chemotherapy are well-known components of treatment plans, maintenance therapies have become meaningful options for doctors in recent years.

Ovarian cancer patients who have a response to platinum-based chemotherapy in the recurrent setting are candidates for PARP inhibitors, one of those being niraparib or ZEJULA, Godoy explained.

Those candidatespatients who recur after a first-line treatment and receive a second line of platinum-based chemotherapyreally need to have that conversation about starting maintenance therapy, she continued.

The current approach of watch-and-wait, where we take them off their chemotherapy or their cytotoxic therapy and just watch and wait to see if the cancer returns, is no longer the only option, Godoy said. Maintenance therapy has changed the paradigm of watching and waiting to see if the cancer returns.

ZEJULA, made by the pharmaceutical company GSK, is a prescription medicine used for the maintenance treatment of adults with ovarian cancer, fallopian tube cancer or primary peritoneal cancer, when the cancer comes back. ZEJULA is used after the cancer has responded (complete or partial response) to treatment with platinum-based chemotherapy. It can also be used for treatment of adults with advanced ovarian cancer, fallopian tube cancer or primary peritoneal cancer who have been treated with three or more prior types of chemotherapy and who have tumors with a certain BRCA gene mutation, or a positive laboratory test, and whose cancer was in response to treatment with platinum-based chemotherapy, and who have progressed more than six months after the last treatment. For treatment in the late-line setting, your healthcare provider will perform a test to make sure that ZEJULA is right for you.

ZEJULA has serious risks such as bone marrow problems called MDS or a type of blood cancer called AML. Low blood cell counts are common. Tell your doctor about any weakness, tiredness, infections, fever, shortness of breath, blood in urine or stool, bruising, bleeding or weight loss. High blood pressure is common and can become serious. Nausea and constipation are also common.

Benefiting From More Recent Treatment Options

The idea of maintenance therapy to treat ovarian cancer is not new, Godoy said. Until recently, however, only intravenous forms of maintenance therapy were available, which required women to receive the treatment in clinics.

More recent treatment options for ovarian cancer include oral medications, like ZEJULA, which give women the ability to take it at home. ZEJULA is taken once a day.

Women living with ovarian cancer are often surprised to learn that maintenance therapies exist, she added. For the newly diagnosed, Godoy offered important advice.

If you have ovarian cancer, ask your OB/GYN to make a referral to a gynecologic oncologist and have a meeting with them to discuss your care, she said. Learn more about current treatments, including maintenance therapy, and be your own best advocate.

Jodi Helmer writes about health, science and innovation.

Important Safety Information

ZEJULA may cause serious side effects, including:

Bone marrow problems called Myelodysplastic Syndrome (MDS) or a type of blood cancer called Acute Myeloid Leukemia (AML). Some people who have ovarian cancer and who have received previous treatment with chemotherapy or certain other medicines for their cancer have developed MDS or AML during treatment with ZEJULA. MDS or AML may lead to death.

Symptoms of low blood cell counts (low red blood cells, low white blood cells, and low platelets) are common during treatment with ZEJULA. They can be a sign of serious bone marrow problems, including MDS or AML. These symptoms may include the following:

Your doctor will do blood tests to check your blood cell counts before treatment with ZEJULA. You will be tested weekly for the first month of treatment with ZEJULA, monthly for the next 11 months of treatment, and from time to time afterward.

High blood pressure is common during treatment with ZEJULA, and it can become serious. Your doctor will check your blood pressure and heart rate at least weekly for the first two months, then monthly for the first year, and as needed thereafter during your treatment with ZEJULA.

Before starting to take ZEJULA, tell your doctor about all of your medical conditions, including if you:

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of ZEJULA include the following:

o Heart not beating regularly

o Nausea

o Constipation

o Vomiting

o Pain in the stomach area

o Mouth sores

o Diarrhea

o Indigestion or heartburn

o Dry mouth

o Tiredness

o Loss of appetite

o Urinary tract infection

o Shortness of breath

o Cough

o Rash

o Changes in liver function or other blood tests

o Pain in your joints, muscles, and back

o Headache

o Dizziness

o Change in the way food tastes

o Trouble sleeping

o Anxiety

o Sore throat

o Changes in the amount or color of your urine

If you have certain side effects, then your doctor may change your dose of ZEJULA, temporarily stop, or permanently stop treatment with ZEJULA.

These are not all the possible side effects of ZEJULA. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

For full prescribing information visit http://www.ZEJULA.com/prescribing-information.

NP-NIR-US-0004

NRPJRNA200001

Continued here:
When Treating Women With Ovarian Cancer, Gynecologic Oncologist Emphasizes Openness And Dedication Throughout Journey - Forbes

Lung-MAP: A five-year recap on the first master protocol trial in cancer research – The Cancer Letter

By adminFebruary 22, 2020Gene Therapy Clinics

publication date: Feb. 21, 2020

Roy S. Herbst, MD, PhD

Lung-MAP Study Chair,

Chief of Medical Oncology,

Yale Cancer Center and Smilow Cancer Hospital;

Ensign Professor of Medicine and Professor of Pharmacology,

Yale School of Medicine

Lyudmila Bazhenova, MD

Lung-MAP Sub-Study Chair,

Professor of Medicine,Medical Oncology,

University of California San Diego School of Medicine,

Moores Cancer Center at UC San Diego Health

Joel Neal, MD, PhD

Lung-MAP Medical Oncology Chair,

Assistant Professor of Medicine,Medical Oncology,

Stanford Cancer Institute,

Stanford University School of Medicine

Saiama N. Waqar, MBBS, MSCI

Lung-MAP Medical Oncology Chair,

Lung-MAP Sub-Study Chair,

Associate Professor of Medicine,

Director, Hematology and Oncology Fellowship Program,

Washington University School of Medicine in St. Louis

This is a formidable challenge. Cancer trials were, and remain, notoriously time-consuming to launch, expensive to run, and difficult to enroll patients to. A deeper understanding of cancer biology and the genomics revolution in medicine have changed how we approach clinical research.When the Lung-MAP trial was launched in June 2014, the goal was simple: Make drug development faster and more collaborativeand do it for lung cancer, the leading cause of cancer death in the United States.

We now have the ability to sequence a patients tumor tissue, determine which proteins or DNA sequences are associated with their cancer, then select a drug designed to attack that type of abnormality in order to create precision, or personalized, treatments. Great news for patients, but tough for researchers.

Once clinical trials incorporate genomic biomarkers, the patient pool splinters. For example, EGFR mutations are observed in 10% to 15% of non-small cell lung cancer patients in the U.S. The ALK gene rearrangement occurs in fewer than 7% of patients, and ROS1 rearrangements are found in only 1% to 2%. In the era of personalized medicine, we are required to sort through a much bigger haystack in order to find much smaller needles.

To address these challenges, the scientific leadership of Lung-MAP adopted an emerging trial design called a master protocolmaking us one of the first to adopt this model in cancer research and the first to do so with drug registration intent.

Master protocols, while complex, are based on the illusion of simplicitymany drugs or patient populations, but only one protocol. No need to open and close the whole trial every time you want to test a new agent or bring on a new group of patients. You simply use the master platform and plug and play independent sub-studies to incorporate promising new treatments.

After an expansion last year, Lung-MAP is open to the vast majority of patients with NSCLC. Its a biomarker-driven protocol that tests several drugs at the same time, a so-called umbrella design. The trial is streamlined, with uniform genomic screening, highly harmonized eligibility requirements, coordinated treatment plans, and consistent endpoints. The sub-studies are also designed to get answers to safety and effectiveness questions quickly and, particularly, to pave the way to regulatory approval.

Finally, because biomarker trials require screening large patient populations, we tapped into the NCIs National Clinical Trials Network. By working within the NCTN, we get access to tens of thousands of lung cancer patients who get their care in more than 2,200 affiliated cancer centers, academic medical centers, and community hospitals and clinics worldwide.

So, here we are, five years after the Lung-MAP launch. What have we accomplished?

Quite a bit. The first NCI-backed precision medicine trial has a track record of accelerating drug discovery and development and fostering innovation in cancer research. We have strong scientific partnerships and a robust drug pipeline. Currently, Lung-MAP has five sub-studies open. In 2020, one more is targeted for activationwith seven others under discussion with pharmaceutical partners. Its our largest pool of potential trial drugs yet.

Lung-MAPs primary mission is to create efficiency and operate collaborativelyall to benefit patients. Weve succeeded on those counts.

Phase II/III trials testing a drug against a biomarker at one or just a few clinical sites historically face slow accrual, especially if the prevalence of the biomarker is low. Similarly, patients with rare molecular biomarkers may have difficulties accessing precision trials due to a lack of comprehensive genomic screening and geographic distance from enrolling sites.

Lung-MAP has opened and completed eight drug-centered sub-studies testing 12 novel therapies since activating in June 2014. Thats 12 new therapies tested in five years. While no comparative studies have been conducted to show how much time master protocols and other innovative trial designs save, we can credibly claim a much faster track record than a typical single drug, single biomarker cancer trial.

Weve also tested a model that was, and remains, a unique public-private partnership. Lung-MAP is a result of years of work by the NCI, NIH, FDA, Friends of Cancer Research, the Foundation for the NIH, SWOG Cancer Research Network and many other research institutions, patient advocacy groups, and industry partners.

This ongoing partnership has been instrumental to fostering innovation and creating a strong value proposition for industry participation. Many Lung-MAP innovations are built into the trial design.

The Lung-MAP leadership team at a Feb. 3 planning meeting held in the Washington, D.C., offices of Friends of Cancer Research

Under Lung-MAP, clinicians have the ability to pre-screen patients while they are on a prior therapy, a feature that shortens the time needed to move a patient into the trial once they progress on front-line therapy. Another innovation: patients who dont qualify for biomarker-driven sub-studies are offered a non-match option. In non-match sub-studies, Lung-MAP patients receive an immunotherapy or another investigational drug expected to work on a range of molecular sub-types.

Additionally, as novel immunotherapies were approved by FDA and quickly became the standard of care in NSCLC, we changed the design in 2015 to allow evaluation of molecularly-targeted compounds to continue in immunotherapy-nave patients, and also provided these cutting-edge drugs as our non-match sub-study for those who were eligible. In 2019, we further revised the trial to allow the addition of sub-studies that evaluate treatment combinations in immunotherapy-resistant patientsan unmet medical need that is increasing as more patients are exposed to immunotherapies.

Drugs and combinations tested on the Lung-MAP trial

Company Names

Drugs Tested

AstraZeneca

AZD4547

AbbVie Inc.

telisotuzumab vedotin

Amgen Inc.

rilotumumab + erlotinib

Bristol-Myers Squibb

nivolumab

nivolumab + ipilimumab

Clovis Oncology, Inc.

rucaparib

Genentech, Inc.

taselisib

Loxo Oncology at Lilly

selpercatinib

MedImmune/AstraZeneca

durvalumab

durvalumab + tremelimumab

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc./ Eli Lilly and Company

pembrolizumab + ramucirumab

Pfizer Inc.

palbociclib

talazoparib

talazoparib + avelumab

Pioneering the use of next-generation sequencing and the Foundation Medicine platform in a large-scale cancer clinical trial.

Lung-MAP was one of the first trials to partner with Foundation Medicine to use its innovative FoundationOne DNA next generation sequencing platform, now an industry standard (F1CDx) for comprehensive genomic screening of all patients.

F1CDx detects gene substitutions, insertions and deletion alterations, and copy number alterations in 324 genes and select gene rearrangements and can evaluate complex molecular targets (e.g., DNA repair deficiency, microsatellite instability, tumor mutational burden, and loss of heterozygosity.

This broad range of molecular signatures defined from F1CDx are used as the molecular biomarkers for Lung-MAP sub-studies, allowing numerous therapies to be evaluated in a biomarker-driven manner and providing historical and real-time information on molecular target prevalence in study populations useful in future Lung-MAP studiesas well as other drug discovery and development efforts. The short turnaround time established for generating screening results from tissue submission to results reporting16 days or less, with an average of 12 daysis critical to the success of Lung-MAP.

Beyond Lung-MAP, F1CDx-derived molecular signatures are now serving as companion diagnostics for 19 drugs, and F1CDx and other NGS platforms are widely used in establishing genomic profiles and diagnostic signatures in clinical research and practice settings. Even with all this success, Foundation Medicine remains a valuable partner and continuously works with us to adapt their platform for new biomarker-driven sub-studies and provide critical insights on developments in the field.

Increasing the amount of genomic screening data available on lung cancer patients, advancing medicine and science.

As of Feb. 6, 2020, Lung-MAP had screened 2,813 patients and paired 799 patients to some type of trial therapy. Data from these patients are being shared to stimulate research that will further our understanding of common NSCLC mutations and to discover future treatment targets.

Influencing the design of other master protocols within and outside of cancer research.

The Lung-MAP design was a pioneer that paved the way for a dozen master protocol trials to launch in recent years, including the landmark NCI-MATCH and Pediatric MATCH cancer trials.

It has also influenced master protocol designs for other diseases, including infectious diseases and Alzheimers disease. Benefits of the Lung-MAP design were highlighted in an October 2018 FDA draft guidance, Master Protocols: Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics.

Establishing a site coordinators committee to provide fast, critical feedback and insights on trial conduct.

Site staff are linchpins to patients when it comes to trial enrollment and management, and we hold their perspectives in high regard when it comes to Lung-MAP conduct.

We selected 12 coordinators based on geography and site-type diversity (e.g. cancer center, community clinic, etc.) to advise us on all aspects of the master protocol to ensure that both patients and staff needs are considered. This committee helps us streamline processes to minimize complexity of the trial.

Providing access to biomarker-targeted drugs and immunotherapies to hundreds of patients, with some success of extending and improving lives.

This broad access is a product of the study design.

As we described above, Lung-MAP patients whose tumor doesnt include a biomarker that matches a trial drug, or who dont otherwise qualify for a biomarker sub-study, still have an option to enroll in a non-match sub-study. These test a novel immunotherapy or other drug expected to have activity across multiple molecular subtypes. Although the squamous NSCLC sub-studies did not lead to the approval of new therapies, it is clear that some patients have benefited from Lung-MAP participation.

For example, about 450 Lung-MAP patients have gotten access to immunotherapies to date. One is Carol Annie Burke, an artist from Savannah, GA, who enrolled on Lung-MAP when she was diagnosed with stage IV squamous cell lung cancer at age 56. After chemotherapy failed to stop her cancer from spreading, she was eligible for a non-match immunotherapy sub-study. The cancer in her lungs, and brain, was gone. The Lung-MAP treatment saved my life, she said.

In addition, trial partner SWOG Cancer Research Network has a unique outreach program with U.S. Department of Veterans Affairs medical centers, which is aimed at getting more military veterans enrolled onto cancer clinical trials. The partnership has given Lung-MAP access to hundreds of veterans, who are at higher risk for lung cancer.

Exploring new, less invasive methods for pairing patients with the best treatments.

With the latest revision of Lung-MAP, the team is collecting blood from patients that consent both during patient screening and while they are being treated on study to allow for retrospective circulating tumor DNA.

These results can eventually be compared to the NGS results and build the appropriate evidence for the eventual use of the less invasive ctDNA testing for clinical placement of patient who are not able to provide a suitable biopsy for participation in the trial, as well as potentially lead to the discovery of blood-based biomarkers of response.

If Lung-MAP has taught us anything these last five years, its that even with a master protocol, you cant stand still. The science moves too fast, always changing the drug development and treatment landscape. This is particularly true of the immunotherapies and targeted drugs we test.

Last year, we expanded Lung-MAP eligibility from squamous cell lung cancer patients to patients with all types of NSCLCmaking investigational drugs available to thousands more eligible people and expanding our patient pool exponentially. That decision to expand has, in part, revived the trial, which is surpassing accrual goals and boasting a pipeline of exciting new drugs, including cutting-edge, promising targeted therapies and the already noted treatments for immunotherapy-refractory patients.

Another reason behind the renewed energy is a change in management structure. There are now eight Lung-MAP study chairstwo each from SWOG, the Alliance for Clinical Trials in Oncology, ECOG-ACRIN Cancer Research Group, and NRG Oncology. This new format of equal representation of all four adult cancer clinical trial groups in the NCI-supported NCTN allowed us to bring in new leaders with broader knowledge of emerging NSCLC therapies, expand access to companies whose drugs are ideal candidates for the trial, and invigorate a broader NCTN commitment to enrolling patients onto the trial.

Continued here:
Lung-MAP: A five-year recap on the first master protocol trial in cancer research - The Cancer Letter

Global Cell and Gene Therapy Consumables Market Revenue Expected to Reach USD 6999 Million By 2027 – Northwest Trail

By adminFebruary 21, 2020Gene Therapy Clinics

Facts and Factors Market Researchhas published a new report titled Cell and Gene Therapy Consumables Market By Product Type (Kits & Buffers, Diagnostic Assay, Culture Medium, and Cryopreservation Media) and By Application/ Therapeutics (Cardiovascular, Urology, Dermatology, Critical Care, Respiratory, Endocrine & Metabolic, Neuroscience, Hematology & Oncology, Obstetrics, Immunology, and Gastroenterology): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018 2027.

According to the report, the globalcell and gene therapy consumables marketis predicted to be valued at approximately USD 641 million in 2018 and is expected to reach a value of around USD 6,999 million by 2027, at a CAGR of around 30.43 % between 2019 and 2027.

Cells are the key building blocks of all living things, while genes are located deep inside the cells. Genes are tiny parts of DNA that carry heritable information and directions for producing proteins that help in building and maintaining the body. Cell and gene therapies are the overlapping domains of biomedical research activities as well as biomedical treatment. The key objective of both these therapies is to treat, prevent, and cure ailments. Moreover, both these approaches have the prospective to lessen the core causes of genetic disorders as well as acquired diseases. However, the functioning of cell and gene treatment varies.

Request Free Sample Copy of Research Report@www.fnfresearch.com/sample/cell-and-gene-therapy-consumables-market-by-product-107

(The sample of this report is readily available on request).

This Free report sample includes:

Furthermore, the main aim of cell treatment is to treat disorders through restoration or alteration of certain sets of cells or through the use of the cells to carry therapy throughout the body. In cell treatment, cells are cultured or altered out of the body before injecting them into the body of the patient. The cells can be acquired from the patient in the form of autologous cells or from a donor in the form of allogeneic cells.

Apparently, the key objective of gene therapy is to treat diseases through the replacement, inactivation, or introduction of genes into cells i.e. either inside the body or outside of the body. Moreover, few of the treatments are considered as both cell and gene treatments. They work by shifting genes in particular types of cells and then injecting them back into the body.

Rising occurrence of target ailments to drive the market trends

The growth of the market during the forecast period is due to the high rate of incidences of chronic ailments including cancer and heart disorders. Apart from this, a rise in the occurrence of these disorders produces lucrative demand for enhanced therapies and this will culminate in the market demand over the forecast period.

Furthermore, a rise in the awareness about the gene & cell therapies will steer the market growth during the period from 2019 to 2027. Nonetheless, conducting randomized control tests will inhibit the expansion of the market during the forecast timeline. However, the growing trend for treating neurodegenerative ailments through the use of gene treatment will proliferate the market growth over the forecast period.

Kits & Buffers segment to dominate the product type landscape in terms of revenue

The growth of the segment during the forecast timespan is due to high demand for the kits & buffers across hospitals & clinics during the cell & gene treatments.

Inquire more about this report before purchase@www.fnfresearch.com/inquiry/cell-and-gene-therapy-consumables-market-by-product-107

Cardiovascular application to accrue massive gains in terms of revenue by 2027

The growth of the segment is due to the high occurrence of heart diseases caused due to the result of inherited disorders like high blood pressure and diabetes.

North America to dominate the regional market growth in terms of value

The growth of the market in the region is due to the major presence of giant players along with the high awareness about these cell & gene treatments. The U.S. is likely to be the major revenue contributor of the region during the forecast timeline.

Some of the key players in the market include Amgen Inc., ATLANTA BIOLOGICALS, bluebird bio, Inc., Cook, Dendreon Pharmaceuticals, LLC, Fibrocell Science, Inc., General Electric, Kolon TissueGene, Inc., Orchard Therapeutics plc., Pfizer, Inc., PromoCell GmbH, RENOVA THERAPEUTICS, Sibiono GeneTech Co. Ltd., Spark Therapeutics, Inc., Vericel, Helixmith Co., Ltd., and Vitrolife.

This report segments the Cell and Gene Therapy Consumables market as follows:

Cell and Gene Therapy ConsumablesMarket:By Product TypeSegment Analysis

Cell and Gene Therapy ConsumablesMarket: ByApplication/ TherapeuticsSegment Analysis

Request Customized Copy of Report @www.fnfresearch.com/customization/cell-and-gene-therapy-consumables-market-by-product-107

Cell and Gene Therapy Consumables Market: Regional Segment Analysis

About Us:

Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our clients/customers conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.

Facts & Factors

Global Headquarters

Level 8, International Finance Center, Tower 2,8 Century Avenue, Shanghai,Postal 200120, ChinaTel: +86 21 80360450

Email:sales@fnfresearch.com

Web:www.fnfresearch.com

See the original post here:
Global Cell and Gene Therapy Consumables Market Revenue Expected to Reach USD 6999 Million By 2027 - Northwest Trail

In Vitro Fertilization Market will Reach USD 36.39 Billion by 2026: Increasing Cases of Infertility Among Men to Positively Influence Growth, says…

By adminFebruary 20, 2020Gene Therapy Clinics

Key Companies Covered in the IVF Market Research Report are Monash IVF, Ovation Fertility, Bloom IVF Centre, Shady Grove Fertility, Bangkok IVF center, Boston IVF, Pelargos IVF, RSMC, Group Ambroise Par Clinic and other key market players.

Pune, Feb. 20, 2020 (GLOBE NEWSWIRE) -- The global In Vitro Fertilization (IVF) Market size is prophesized to reach USD 36.39 billion by 2026, with a CAGR 10.1% by 2026. This is attributable to the increasing cases of infertility among people worldwide. This is more common in males than female partners. The market value was USD 16.89 billion in 2018. IVF is a fertilization process wherein sperm and eggs are retrieved as a sample and are combined manually in laboratories. Various studies show that almost half a million babies are born by this process or other assistant reproductive processes. Such factors are responsible for the in vitro fertilization market growth.

Fortune Business Insights latest report, titled, In Vitro Fertilization (IVF) Market Size, Share & Industry Analysis, By Type (Conventional IVF, and IVF with ICSI), By Procedure (Fresh Non-donor, Frozen Non-donor, Fresh Donor, and Frozen Donor), By End User (Hospitals, and Fertility Clinics) and Regional Forecasts, 2019-2026 provides a 360-degree overview of the market and its parameters. These include growth drivers, restraints, challenges, and opportunities. The report also provides detailed segmentation of the market with market figures such as base and forecast figure and the compound annual growth rates (CAGRs) as well. Besides this, the report provides interesting insights into the market, key industry developments, and other IVF market trends. The report is available for sale on the company website.

Nowadays, people are more inclined towards career goals rather than family planning, and therefore often tend to opt for late pregnancies. The increasing number of such cases is a major in vitro fertilizer market driver, as mentioned earlier, since complicated cases are often resolved by opting for IVF treatment. This is more common in nations such as the UK, Japan, and the U.S. Besides this, the rise in the number of male infertility is anticipated to increase the adoption of IVF treatment and thus accelerate the in vitro fertilization market size in the coming years. Besides this, government-supported reimbursement policies and awareness programs are aiding the overall in vitro fertilization market growth of the region.

Analysts at Fortune Business Insights said high expenses and risks related to the in vitro fertilization process (IVF) and Intracytoplasmic sperm injection (ICSI) may cause hindrance to the overall in vitro fertilization market revenue. Nevertheless, factors such as increasing obesity cases among people, infertility among men, the practice of sedentary lifestyle, and others are likely to create lucrative IVF market growth opportunities in the coming years.

Europe holds a dominant in vitro fertilization market share with a revenue of USD 7.57 billion generated in the year 2018. This is attributable to the rise in the prevalence of infertility and the increasing popularity of IVF treatment in the region. On the other side, the market in North America will witness steady growth on account of the high cost associated with ICSI and IVF treatment. As per the FertilityIQ data, 2017, in the U.S., the average expenditure of a patient undergoing a single IVF cycle is USD 22,000. Thus, patients in the U.S are travelling to other countries for IVF treatment citing lower costs.

Companies are Investing in Construction of New Fertility Centers for Revenue Generation

Boston IVF, Pelargos IVF, and Monash IVF are currently dominating the market. In vitro fertilization market manufacturers are developing new centers with efficient and high-quality treatment in remote locations for speeding their own revenue generation and making their mark in the market competition. This will ultimately accelerate the overall IVF market size.

Significant Industry Developments in In Vitro Fertilization Market:

May 2019 A new embryo screening test was developed by scientists at Monash IVF for reducing the risk of miscarriage at the time of IVF treatment.

July 2019 The opening of a new full-service IVF center at the Westshore office at Tampa, Florida, was announced by Shady Grove Fertility. The main objective behind the opening of this center is to offer affordable and high-quality fertility treatment options to the regional people.

List of key Companies Operating in the In Vitro Fertilization (IVF) Market include:

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/in-vitro-fertilization-ivf-market-102189

Detailed Table of Content:

TOC Continued.!

Request for Customization: https://www.fortunebusinessinsights.com/enquiry/customization/in-vitro-fertilization-ivf-market-102189

Have a Look at Related Reports:

In-vitro Diagnostics (IVD) Market Size, Share & Industry Analysis, By Product Type (Instruments, Reagents & Consumables), By Technique (Immunodiagnostics, Clinical Chemistry, Molecular Diagnostics, Point of Care, Hematology and Others), By Application (Infectious Diseases, Cardiology, Oncology, Gastroenterology, Others), By End User (Clinical Laboratories, Hospitals, Physicians Offices, Others) and Regional Forecast, 2019 2026

Assisted Reproductive Technology (ART) Market Size, Share & Industry Analysis, By Technique (In-Vitro Fertilization (IVF), Artificial Insemination (AI-IUI), Frozen Embryo Transfer (FET), and Others), By Procedure (Fresh Donor, Fresh Non-donor, Frozen Donor, and Frozen Non-donor), By End User (Fertility Clinics, and Hospitals) and Regional Forecast, 2019-2026

Biomarkers Market Size, Share & Industry Analysis, By Indication (Oncology, Cardiology, Neurology, and Others), By End User (Pharmaceutical & Biotechnology Companies, Diagnostics & Research Laboratories, Hospitals & Specialty Clinics, and Others), and Regional Forecast, 2019-2026

Neuroendoscopy Devices Market Size, Share & Industry Analysis, By Product Type (Rigid Neuroendoscopes, Flexible Neuroendoscopes), By Application Type (Transnasal Neuroendoscopy, Intraventricular Neuroendoscopy, Transcranial Neuroendoscopy), By End User (Hospitals, Specialty Clinics, Others) and Regional Forecast, 2019-2026

Next-Generation Sequencing (NGS) Market Size, Share and Industry Analysis By Type (Products, Instruments & Software, Consumables, Services), By Application (Diagnostics, Research), By End User (Research Institutes, Healthcare Facilities & Diagnostic Centres, Pharmaceutical & Biotechnological Companies, Contract Research Organization) & Regional Forecast, 2019 2026

Regenerative Medicine Market Size, Share and Industry Analysis By Product (Cell Therapy, Gene Therapy, Tissue Engineering, Platelet Rich Plasma), By Application (Orthopaedics, Wound Care, Oncology), By Distribution Channel (Hospitals, Clinics) & Regional Forecast, 2019 2026

Genomics Market Size, Share and Industry Analysis By Type (Products, Services), Technology (Polymerase Chain Reaction, Next-generation Sequencing, Microarray, Sanger Sequencing), Application (Diagnostics, Research), End-User (Research Institutes, Healthcare Facilities & Diagnostic Centers, Pharmaceutical & Biotechnological Companies, Contract Research Organization (CROs)) & Regional Forecast, 2019 - 2026

Contract Research Organization (CRO) Services Market Size, Share and Industry Analysis By Service Type (Discovery, Pre-Clinical, Clinical, Laboratory Services), By Application (Oncology, Cardiology, Infectious Disease, Metabolic Disorders, Others), By End User (Pharmaceutical & Biotechnological Companies, Medical Device Companies, Academic & Research Institutes, Others), and Regional Forecast 2019-2026

Immunology Market Size, Share and Industry Analysis By Drug Class (Monoclonal antibody (mAb), Fusion Proteins, Immunosuppressant, Polyclonal antibody (pAb), Others), By Disease Indication (Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, Prophylaxis of Organ Rejection, Others), By Distribution Channel, and Regional Forecast 2019-2026

Immunodiagnostics Market Size, Share and Industry Analysis By Product Instruments, Reagents & Consumables), By Application (Oncology & Endocrinology, Hepatitis & Retrovirus, Cardiac Markers, Infectious Diseases), By End user (Clinical Laboratories, Hospitals, Physicians Offices), By End-user(Hospitals, Dental Clinics, Academic & Research Institutes) and Regional Forecast, 2019 2026

Orthobiologics Market Size, Share and Industry Analysis by Product Type (Viscosupplements, Bone Growth Stimulators, Demineralized Bone Matrix, Synthetic Bone Substitutes, Stem Cells, Allografts), By Application (Spinal Fusion, Maxillofacial & Dental, Soft Tissue Repair, Reconstructive & Fracture Surgery), By End User (Hospitals, Ambulatory Surgical Centers, Speciality Clinics), and Regional Forecast 2019-2026

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:Fortune Business Insights Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India.Phone:US :+1 424 253 0390UK : +44 2071 939123APAC : +91 744 740 1245Email: sales@fortunebusinessinsights.comFortune Business InsightsLinkedIn | Twitter | Blogs

Press Release: https://www.fortunebusinessinsights.com/press-release/in-vitro-fertilization-ivf-market-9606

Excerpt from:
In Vitro Fertilization Market will Reach USD 36.39 Billion by 2026: Increasing Cases of Infertility Among Men to Positively Influence Growth, says...

Global Veterinary X-ray Market is Expected to Reach USD 1,167.47 Million by 2025 : Fior Markets – GlobeNewswire

By adminFebruary 20, 2020Gene Therapy Clinics

Newark, NJ, Feb. 20, 2020 (GLOBE NEWSWIRE) -- As per the report published by Fior Markets, theglobal veterinary x-ray market is expected to grow from USD 651.07 Million in 2017 to USD 1,167.47 Million by 2025 at a CAGR of 7.81% during the forecast period from 2018-2025.

Radiology systems are the most preferred diagnostic tools a veterinarian uses to diagnose diseases in animals. It contains of diagnostic medical descriptions including ultrasound, magnetic resonance tomography, magnetic resonance imaging and atomic imaging. This is a non-invasive way to diagnose the disease. It is a painless procedure, however, animals are often anesthetized to reduce anxiety and stress during the procedure. The rise in the number of pets and the increase in awareness about the well-being of pets is driving the growth of this sector. According to the American Pet Products Association, in 2016, American families had approximately 35% of cats and 44% of dogs, making them around 85.8 million cats and 78 million dogs owned by the United States

The global market for veterinary X-rays is expected to grow rapidly during the forecast period, due to the increasing incidence of animal bone diseases, the increasing number of pets around the world, and the increase in the number of veterinary practitioners worldwide, as it is the main factor driving the market. The high cost of veterinary X-ray tools and the shortage of skilled veterinary technicians may limit market growth. However, high levels of pet insurance may boost future market opportunities.

DOWNLOAD FREE SAMPLE REPORT AThttps://www.fiormarkets.com/report-detail/376062/request-sample

Key players operating in the global veterinary X-ray market are IDEXX Laboratories, Fujifilm, Onex Corporation, Agfa-Gevaert Group, Sound Technologies, Sedecal, Examion, Canon, DRE Veterinary, Heska Corporation, Fovea, Clearvet, Control-X Medical, Allpro Imaging, Vetel Diagnostics, Pixxgen and Konica Minolta among others. To enhance their market position in the global veterinary X-ray market, the key players are now focusing on adopting the strategies such as recent developments, product innovation, joint venture, mergers & acquisitions, collaborations, and partnership. Major firms are increasingly investing on research and development activities and development of newer products.

Computed radiography systems is dominating the segment and was valued around USD 286.44 Million in 2017

The technology segment is classified into computed radiography systems segment, direct radiography systems and film-based radiography systems. Computed radiography systems is dominating the segment and was valued around USD 286.44 Million in 2017. Increasing demand for affordable digital X-ray equipment and benefits offered by CR systems over other technologies are contributing for the growth of the segment.

The digital X-rays segment held the largest share of around 56.31% in 2017

Type section includes digital X-rays and analog X-rays. The digital X-rays segment held the largest share of around 56.31% in 2017. X-ray systems offer various benefits over analog systems, which include less costly, improved efficiency, and patient-centric imaging are some of the factors driving the growth of the segment.

The Stationary X-Ray Systems segment is dominated and expected to witness the highest market share of 56 % in the forecast period

The segment is classified into stationary x-ray systems and portable x-ray systems. The stationary x-ray systems is dominated and expected to witness the highest market share of 56% in the forecast period. While new technology advancement and rising use of portable x-ray systems are boosting this segment.

The small companion animals segment is dominated and is expected to held largest share of 61.17% in 2017

Animal type segment includes small companion animals and large animals. The small companion animals segment is dominated and is expected to held largest share of 61.17% in 2017. Increased adoption of pets, growing companionship and demand of highly accurate diagnostic solutions are boosting the growth of the segment.

The orthopedic & trauma segment is dominating and was valued around USD 214.83 million in 2017

Application segment is bifurcated into orthopedics & trauma, dental applications, oncology and other applications. Orthopedic & trauma segment is dominating and was valued around USD 214.83 million in 2017 due to increase in injuries among animals and availability of animal care facilities are contributing to the growth of the segment.

The veterinary hospitals & academic institutes segment is anticipated to grow with the highest CAGR of 9.14% in the forecast period

End user section includes veterinary hospitals & academic institutes and veterinary clinics. The veterinary hospitals & academic institutes segment is anticipated to grow with the highest CAGR of 9.14% in the forecast period. The growth can be accredited to developments in technologies for cost-effective, fast and precise diagnostic tools for animal healthcare.

Browse full report with TOC athttps://www.fiormarkets.com/report/global-veterinary-x-ray-market-by-technology-type-direct-376062.html

Regional Segment Analysis of the Veterinary X-ray market

The regions analysed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. North America region captured the largest share of global veterinary X-ray market and was valued in USD 318.99 Million in 2017 whereas Asia pacific is expected to attain the lucrative growth in the forecast period. North America region is expected to dominate the market due to pet adoption coupled with increasing healthcare expenditure and increase in R&D with growing demand for veterinary equipment. Asia pacific is expected to register the highest growth in the forecast period owing to growing demand for veterinary products and availability of low-cost animal health products are anticipated to drive the growth. Figured radiography and film-based radiography are inexpensive in this region as compared to industrialised regions.

About the report:

The global veterinary x-ray market is analysed on the basis of value (USD Million). All the segments have been analyzed on global, regional and country basis. The study includes the analysis of more than 30 countries for each segment. The report offers an in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The study includes porters five forces model, attractiveness analysis, raw material analysis, supply, demand analysis, competitor position grid analysis, distribution and marketing channels analysis.

For Instant Purchase:

Customization of the Report:

About Fior Markets

Avinash DHead of Business DevelopmentPhone:+1-201-465-4211Email:sales@fiormarkets.comWeb:www.fiormarkets.com

To Read Top Industries Reports, Visit our Affiliated Website: https://www.mrinsights.biz/

Excerpt from:
Global Veterinary X-ray Market is Expected to Reach USD 1,167.47 Million by 2025 : Fior Markets - GlobeNewswire

Parkinsons Disease Treatment Market 2019- Global Industry Analysis, by Key Players, Segmentation, Application, Demand and Forecast by 2025 – Instant…

By adminFebruary 15, 2020Gene Therapy Clinics

Global Parkinsons Disease Treatment Market 2019-2025 Overview

The Parkinsons disease treatment market growth was driven because of increase in the geriatric population and the rise in the occurrence of the Parkinsons disease and the funding for research.

Global Parkinsons disease treatment market is anticipated to experience the substantial growth during the forecast period. Growth in the occurrence of the Parkinsons diseases is projected to supplement the growth of global Parkinsons disease treatment market in the coming future. In addition, the combined treatments supporting in the long action of constant dopaminergic stimulation medicines, neural transplantation and gene therapy is expected to fuel the Parkinsons disease treatment market growth.

Request sample copy of this report at: https://www.adroitmarketresearch.com/contacts/request-sample/615

Parkinsons disorder is a neurological disorder affecting the movements of body. There are five stages of this disease and can hamper the individuals leg & hand movements, facial expressions getting worse with the growing age. Increase in the elderly population related to the rise in the investments in the activities of research & development, growth in the awareness for healthcare and the neurological disorders are the factors driving the global Parkinsons disease treatment market growth over the forecast period. On the other hand, due to the presence of the other treatments is hampering the Parkinsons disease treatment market growth.

Current developments in the Parkinsons disease treatment, for example, combined treatment to continue the effect of constant dopaminergic stimulation medicines, gene therapy, neural transplantation, neuroprotective treatment to reduce the disease prediction and support for the neurostimulation tools are estimated to provide large development in the global Parkinsons disease treatment market growth during the forecast period. Moreover, major characteristics that are fueling the requirement and demand for the global parkinsons disease treatment market are prevalence of parkinsons disease and growth in the geriatric population. Two important characteristics that are responsible to boost the Parkinsons disease treatment market development are prevalence of the neurodegenerative syndrome and rise in the elderly population. Although, increase in the medicines in the pipeline and growth in the R&D activities are anticipated to surge the Parkinsons disease treatment market size. In addition, lack of skills for the early diagnosis and large spending on treatment is projected to bolster the development of global Parkinsons disease treatment market.

Get Discount:https://www.adroitmarketresearch.com/contacts/discount/615

Key factor driving the growth of Parkinsons disease treatment market is the growth in the acceptance of the treatment for Parkinson disease in healthcare sector. For treating and detecting the dysfunctioning of the human beings central nervous system and the neurological damage because of lack of cells and nerves are the main function of Parkinsons disease treatment market.

Global Parkinsons disease treatment market is segmented into end-use, distribution channel, drug class and region. Based on end-use, market is divided into clinics and hospitals. On the basis of distribution channel, market is divided into retail pharmacies, online pharmacies and hospital. On considering the drug class, market is divided into MAO inhibitors, Levopoda/ Carbidopa and Dopamine Receptor Agonists.

Geographically, regions involved in the development of Parkinsons disease treatment market growth are Europe, North America and Asia Pacific. Asia Pacific is anticipated to show the rapid growth because of the increase in the trend of medical tourism and medical infrastructure. North America holds the largest

Read details of the report athttps://www.adroitmarketresearch.com/industry-reports/parkinsons-disease-treatment-market

Parkinsons disease treatment market share. Europe is dominating the Parkinsons disease treatment market because of the maximum market revenue in the coming years.

Key players involved in the Parkinsons disease treatment market analysis are Teva Pharmaceutical Industries, Novartis AG, Impax Laboratories and GlaxoSmithKline.

Key Segments in the Global Parkinsons Disease Treatment Market are-

By End-Use, market is segmented into:

By Distribution Channel, market is segmented into:

By Drug Class, market is segmented into:

By Regions market is segmented into:

What to expect from the Global Parkinsons Disease Treatment Market report?

Predictions of future made for this market during the forecast period.

Information on the current technologies, trends, devices, procedures, and products in the industry.

Detailed analysis of the market segmentation, depending on the types, devices, and products.

Government regulations and economic factors affecting the growth of the market.

An insight into the leading manufacturers.

Regional demographics of the market.

Who should buy this report?

Venture capitalists, Investors, financial institutions, Analysts, Government organizations, regulatory authorities, policymakers ,researchers, strategy managers, and academic institutions looking for insights into the market to determine future strategies

Else place an Inquire before Purchase Parkinsons Disease Treatment Market Size, Status and Forecast 2025:https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/615

About Us:

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Read the original post:
Parkinsons Disease Treatment Market 2019- Global Industry Analysis, by Key Players, Segmentation, Application, Demand and Forecast by 2025 - Instant...

Cancer Biological Therapy Market Top Key Players, Size, Global Share, Trend, Segmentation, Demand, Opportunities And Forecasts To 2025 – Chronicle 99

By adminFebruary 15, 2020Gene Therapy Clinics

The Report titled: Global Cancer Biological Therapy Market Analysis: Production, Capacity, Sales, Revenue, Trends, Revenue Share, and Forecast till 2025

The authors of the Cancer Biological Therapy Market Report have done extensive study of the global Cancer Biological Therapy market keeping in mind the key aspects such as growth determinants, opportunities, challenges, restraints, and market developments. This analysis will enrich the ability of the companies involved in the global Cancer Biological Therapy market to make precise decisions. The report also emphasizes on the current and future trends in the global Cancer Biological Therapy market, which may bode well for the global Cancer Biological Therapy market in the coming years.

Introduction:, Cancer is the leading and second largest cause of death across the globe. The disease is characterized by disordered and deregulated cellular and stromal explosion along with reduced cell death and growth factor deprivation, and such other factors. There are many biological therapies that have been approved and being used by various cancer specialists across the globe. While there are many other therapies also which are under the research and development phase and are yet to be available for commercial use., , , Biological therapy treatment is treatment process which is performed with the help of living organisms, parts of living organisms or laboratory manufactured version of such content. Most of the biological therapies uses bacteria or vaccines to mimic the bodys immune system to act against cancer developing cells. These various types of biological therapies, which are most of the times stated to biological response modifier therapy or immunotherapy, but these types of therapies do not always target cancer cells directly. Further there are other biological therapies like sections of genetic material or antibodies which are commonly known as DNA or RNA, do aim at targeting cancer cells directly. There are some other types of biological therapies that inhibit specific molecules involved in development and growth of cancer tumor. Such therapies known as cancer targeted therapies. , The Europe, Middle East and Africa Cancer Biological Therapy market is expected to reach US$ 29,776.3 million by 2023 at a CAGR of 5.0% during the forecast period., , , EMEA Cancer Biological Therapy Market is further segmented into type of therapy which include Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Cancer Growth Blockers, Interferons, Interleukins, Gene Therapy, Targeted Drug Delivery, Colony Stimulating Factor, Cancer Vaccines and other therapies. The Monoclonal Antibodies segment includes sub segment namely Naked Monoclonal Antibodies. Interferon segment is further sub segmented into Alpha Interferon, Beta Interferon and Gamma Interferon., , , On the basis on end users cancer biological therapy market is segmented into Hospitals & Clinics, Laboratories, Cancer Research Centers and other end users. Hospitals & Clinics accounted for the largest market share of EMEA cancer biological therapy market. Hospitals & Clinics commands maximum share of EMEA cancer biological therapy market in 2015. , On the basis of region, Europe accounted for the largest market share in biological therapy market. While Middle East and Africa region is expected to grow with a steady pace during forecast period.

Get Free Exclusive Sample of this Premium Report at @ https://www.esherpamarketreports.com/request-sample/es-193383/

Table of Contents:1. Research Methodology 2. Executive Summary 3. Market Overview 3.1. Definition 3.2. Industry Value Chain Analysis 3.3. Porters 5 Forces 3.4. Regulations 4. Market Dynamics 4.1. Introduction 4.2. Drivers 4.3. Constraints 4.4. Trends 5. Global Cancer Biological Therapy Market Segmentation, Forecasts and Trends by Application 6. Global Cancer Biological Therapy Market Segmentation, Forecasts and Trends by Technology 7. Global Cancer Biological Therapy Market Segmentation, Forecasts and Trends by Region 8. Competitive Intelligence 8.1. Company Market Share Analysis 9. Company Profiles 10. Investment Opportunities

Click Here For Detailed Table Of Contents

Enquire before purchasing this report @ https://www.esherpamarketreports.com/pre-order-enquiry/es-193383

Key Highlights of Cancer Biological Therapy Market Report:

Reasons To Buy:

Purchase this Report with Full Access @ https://www.esherpamarketreports.com/purchase/es-193383/

Name: Jason George

Email: sales@esherpamarketreports.com

Call :USA: +1 408 757 0510

Organization: eSherpa Market Reports

About Us:

eSherpa Market Reports is the credible source for gaining the market research reports that will exponentially accelerate your business. We are among the leading report resellers in the business world committed towards optimizing your business. The reports we provide are based on a research that covers a magnitude of factors such as technological evolution, economic shifts and a detailed study of market segments.

Here is the original post:
Cancer Biological Therapy Market Top Key Players, Size, Global Share, Trend, Segmentation, Demand, Opportunities And Forecasts To 2025 - Chronicle 99

Outlook on the Gene Therapy for CNS Disorders Market to 2025 by Application, – News by aeresearch

By adminFebruary 1, 2020Gene Therapy Clinics

New Market Research Report on Gene Therapy for CNS Disorders Market size | Industry Segment by Applications (Hospitals, Clinics and Others), by Type (Ex Vivo and In Vivo), By Regional Outlook - Global Industry Analysis, Size, Share, Growth, Opportunity, Latest Trends, and Forecast to 2025.

Regional analysis is another highly comprehensive part of the research and analysis study of the global Gene Therapy for CNS Disorders market presented in the report. This section sheds light on the sales growth of different regional and country-level Gene Therapy for CNS Disorders markets. For the historical and forecast period 2020 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Gene Therapy for CNS Disorders market.

This report on Gene Therapy for CNS Disorders Material Market delivers an in-depth analysis that also comprises an elaborate assessment of this business. Also, segments of the Gene Therapy for CNS Disorders Material market have been evidently elucidated in this study, in addition to a basic overview pertaining to the markets current status as well as size, with respect to the profit and volume parameters.

Request Sample Copy of this Report @ https://www.aeresearch.net/request-sample/64581

Global market focusing on major players of Gene Therapy for CNS Disorders market:

This Gene Therapy for CNS Disorders Market Research/analysis Report Contains Answers to your following questions:

Market segmentation, by product types:

Market segmentation, by applications:

Highlights of Report:

An all-inclusive framework of the geographical terrain:

Request Customization on This Report @ https://www.aeresearch.net/request-for-customization/64581

Stem Cell Clinic

Stem Cell News

Category Archives: Gene Therapy Clinics

Global Genetic Testing Services Market is Expected to Reach USD 67.1 Billion by 2025 : Fior Markets – GlobeNewswire

Global Genetic Testing Services Market is Expected to Reach USD 67.1 Billion by 2025 : Fior Markets – Yahoo Finance

When Treating Women With Ovarian Cancer, Gynecologic Oncologist Emphasizes Openness And Dedication Throughout Journey – Forbes

Lung-MAP: A five-year recap on the first master protocol trial in cancer research – The Cancer Letter

Global Cell and Gene Therapy Consumables Market Revenue Expected to Reach USD 6999 Million By 2027 – Northwest Trail

In Vitro Fertilization Market will Reach USD 36.39 Billion by 2026: Increasing Cases of Infertility Among Men to Positively Influence Growth, says…

Global Veterinary X-ray Market is Expected to Reach USD 1,167.47 Million by 2025 : Fior Markets – GlobeNewswire

Parkinsons Disease Treatment Market 2019- Global Industry Analysis, by Key Players, Segmentation, Application, Demand and Forecast by 2025 – Instant…

Cancer Biological Therapy Market Top Key Players, Size, Global Share, Trend, Segmentation, Demand, Opportunities And Forecasts To 2025 – Chronicle 99

Outlook on the Gene Therapy for CNS Disorders Market to 2025 by Application, – News by aeresearch